



Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

October 31, 2017

(Oxford, UK and Conshohocken, US, 31 October 2017) Immunocore Limited, the world's leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. This year's SITC is taking place 8 – 12 November, 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland in USA.

Poster Presentation Information:

Title: Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
Authors: Richard Carvajal, Takami Sato, Alexander N. Shoushtari, Joseph Sacco, Paul Nathan, Marlana Orloff, Pippa Corrie, Neil Steven, Jeff Evans, Jeffrey Infante, Mario Sznol, Clive Mulatero, Omid Hamid, Leonel Hernandez-Aya, Nicola Little, Cheryl McAlpine, David Krige, Namir J. Hassan, Sanjay Patel, Ann-Marie Hulstine, Christina M. Coughlin, Mark R. Middleton
Category: Clinical Trials (Completed)
Date: Saturday 11 November 2017
Time: 12:30 – 14:00 & 18:30 – 20:00
Abstract Number: P208

The details of the clinical trial can be found on clinicaltrials.gov.

Furthermore, a poster presenting findings from a study mapping the treatment pathway for patients with metastatic uveal melanoma in England will be presented.

Title: Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study
Authors: Elisabeth Adams, Chih-Yuan Cheng, Joseph Sacco, Sarah Danson, Pippa Corrie, Paul Nathan, Peter Szlosarek, Joanne Upton, Abolore Amuludun, Toby Toward
Category: Best Practices for Improving Cancer Immunotherapy Treatment Administration and Polypharmacy Management
Date: Friday 10 November 2017
Time: 12:30 – 14:00 & 18:30 – 20:00
Abstract: P437

To view the posters, please visit the SITC website at <https://www.sitcancer.org/2017/abstracts/info>

SITC is the world's leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Please click on the link below to download the full Press Release: